PuraPharm Corporation Limited provided earnings guidance for the year ended December 31, 2017. The board of directors of the company announced that based on the preliminary assessment of the unaudited consolidated management accounts of the group for the year ended December 31, 2017 and other information currently available to the board, although the overall revenue of the group for the year ended 31 December 2017 was higher than last year, it is expected that the group's profit for the year ended 31 December 2017 will decline significantly by more than 90% and may even record a loss, as compared to its profit of approximately HKD 32.2 million for the year ended 31 December 2016. Such significant decline was mainly attributable to: the decline in sales of the Group's China Concentrated Chinese Medicine Granules CCMG' segment resulted from the decrease in sales quantity to the group's distributors mainly in the fourth quarter of 2017, which normally is the peak season for the group's China CCMG segment. Such decline is mainly due to the political uncertainties arising from the potential liberalization of the CCMG market in China to other manufacturers and competition from the existing competitors. As a result, the group's distributors reduced their purchase of CCMG products from the Group and kept their inventories of the group's CCMG products at a low level.